Top

Journal of Assisted Reproduction and Genetics

Published in:

01-03-2012 | ASSISTED REPRODUCTION TECHNOLOGIES

Pregnancy outcomes in oocyte donation recipients: vaginal gel versus intramuscular injection progesterone replacement

Authors: Brian M. Berger, James A. Phillips

Published in: Journal of Assisted Reproduction and Genetics | Issue 3/2012

Abstract

Purpose

Compare outcomes with vaginal gel versus intramuscular progesterone replacement in donor oocyte recipients.

Methods

A single-center retrospective analysis (January 2004–December 2006) evaluated pregnancy outcomes (serum human chorionic gonadotropin, implantation, clinical pregnancy, delivery, total pregnancy loss rates) for 225 recipients of embryos from donor (aged <32 years) oocytes. Vaginal progesterone gel (Crinone® 8%; 90 mg twice daily; n = 105) or intramuscular progesterone (50 mg once daily; n = 120) was started the afternoon of oocyte retrieval and continued until a negative pregnancy test or 10 weeks’ gestation.

Results

There were no statistically significant differences between groups for the five pregnancy outcomes; numerical results favored vaginal progesterone in all cases. Confidence intervals showed vaginal gel was within, or <1% from, a noninferiority limit of 10% versus intramuscular progesterone for four of five pregnancy outcomes.

Conclusions

Pregnancy outcomes were comparable for progesterone replacement with vaginal gel and intramuscular progesterone in an oocyte donation program.

Dey SK, Johnson DC. Embryo-uterine interaction in implantation. Life Sci. 1980;27:2381–4.PubMedCrossRef

Dey SK, Davis DL, Hersey RM, Weisz J, Johnson DC, Pakrasi PL. Physiological aspects of blastocyst uterine interaction. J Biosci. 1984;6 Suppl 2:23–31.CrossRef

Emiliani S, Delbaere A, Devreker F, Englert Y. Embryo-maternal interactive factors regulating the implantation process: implications in assisted reproduction. Reprod Biomed. 2005;Online 10:527–40.

de Ziegler D, Fanchin R, Massonneau M, Bergeron C, Frydman R, Bouchard P. Hormonal control of endometrial receptivity. The egg donation model and controlled ovarian hyperstimulation. Ann NY Acad Sci. 1994;734:209–20.PubMedCrossRef

Punyadeera C, Verbost P, Groothuis P. Oestrogen and progestin responses in human endometrium. J Steroid Biochem Mol Biol. 2003;84:393–410.PubMedCrossRef

Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotropin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod. 1999;14:1944–8.PubMedCrossRef

Licciardi FL, Kwiatkowski A, Noyes NL, Berkley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril. 1999;71:614–8.PubMedCrossRef

Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12:1073–9.PubMedCrossRef

Ciccinelli E, de Ziegler D, Bulletti C, Matteo MG, Schronauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–6.CrossRef

10.

Levine H. Luteal support from the vaginal progesterone (P) gel Crinone 8%: preliminary results of multicenter trial show higher pregnancy rates than historical controls. J Soc Gynecol Investig. 2000;7 Suppl 571:203A.

11.

Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–8.PubMedCrossRef

12.

Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril. 2008;89:485–7.PubMedCrossRef

13.

Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007;87:83–7.PubMedCrossRef

14.

Anserini M, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni R. Luteal phase support in assisted reproduction cycles using either vaginal (Crinone 8) or systemic (Prontogest) progesterone: results of a prospective, randomized study. Minerva Ginecol. 2001;53:297–301.PubMed

15.

Chantilis SJ, Zeitoun KM, Patel SI, Johns DA, Madziar VA, McIntire DD. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–9.PubMedCrossRef

16.

Ottoson UB, Carlstrom K, Damber JE, von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol. 1984;91:1111–9.PubMedCrossRef

17.

Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. J Reprod Med. 1999;44:141–7.PubMed

18.

Gibbons WE, Toner JP, Hammacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998;69:96–101.PubMedCrossRef

19.

Williams SC, Donahue J, Muasher SJ. Vaginal progesterone therapy during programmed cycles for frozen embryo transfer: an analysis of serum progesterone levels and pregnancy rates [Abstract P-363]. Fertil Steril. 2000;74 Suppl 1:S209.CrossRef

20.

Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature. 1984;307:174–5.PubMedCrossRef

21.

Crinone® 4% and Crinone® 8% (progesterone gel) [prescribing information], Livingston, NJ: Columbia Laboratories, Inc. 2009.

22.

Witmyer J, Wang S, Alper M, Powers R. HIP embryos: effective criteria for high pregnancy rates with low high order multiples. Fertil Steril. 2003;80:S139–40.CrossRef

23.

Greenblatt DJ, Allen MD. Intramuscular injection site complications. JAMA. 1978;49:536.

24.

Al-Shawaf T, Zosmer A, Dirnfeld M, Grudzinkas G. Safety of drugs used in assisted reproduction techniques. Drug Saf. 2005;28:513–28.PubMedCrossRef

25.

Penzias A, Alper M. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed. 2003;Online 6:187–295.

26.

Phipps WR, Benson CB, McShane PM. Severe thigh myositis following intramuscular progesterone injection in an in vitro fertilization patient. Fertil Steril. 1988;49:536–7.PubMed

27.

Phy J. Hypersensitivity to progesterone-in-oil after in vitro fertilization and embryo transfer. Fertil Steril. 2003;80:1272–5.PubMedCrossRef

28.

Kline DG, Kim D, Midha R, Harsh C, Tiel R. Management and results of sciatic nerve injuries: a 24-year experience. J Neurosurg. 1998;89:13–23.PubMedCrossRef

29.

Bouckaert Y, Robert F, Englert Y, De Backer D, De Vuyst P, Delbaere A. Acute eosinophilic pneumonia associated with intramuscular injection of progesterone as luteal phase support after IVF: case report. Hum Reprod. 2004;19:1806–10.PubMedCrossRef

30.

Veysman B, Vlahos I, Oshva L. Pneumonitis and eosinophilia after in vitro fertilization. Ann Emerg Med. 2006;47:472–5.PubMedCrossRef

Title: Pregnancy outcomes in oocyte donation recipients: vaginal gel versus intramuscular injection progesterone replacement
Authors: Brian M. Berger
James A. Phillips
Publication date: 01-03-2012
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 3/2012
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-011-9691-9

At a glance: The STEP trials

Springer Medicine

Pregnancy outcomes in oocyte donation recipients: vaginal gel versus intramuscular injection progesterone replacement

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

Epigenetics and its role in male infertility

Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization

Comments on the AZFc markers used for screening of Yq microdeletions

When ONE is the not-so-loneliest number!

Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report

Elevated day 3 FSH/LH ratio: a marker to predict IVF outcome in young and older women